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1. INTRODUCTION 
The isoquinoline skeleton is a heterocyclic ring system that frequently occurs among 
both natural and synthetic bioactive molecules. Isoquinoline derivatives are applied for many 
therapeutic purposes. On the basis of the spasmolytic activity of the benzylisoquinoline 
alkaloid papaverine (1), many synthetic analogues have been developed (e.g. drotaverine, 
ethaverine, moxaverine and dimoxyline). The antitussive noscapine (2) and the expectorant 
emetine are also naturally-occurring isoquinoline derivatives with current pharmaceutical 
applications. The list of synthetic isoquinoline derivatives of practical pharmacological 
importance includes the angiotensin-converting enzyme inhibitor quinapril (3) and moexipril, 
the local anaesthetic quinisocaine (4), the anthelminthic praziquantel (5), the antidepressant 
nomifensine and the antiviral nelfinavir (6) (Fig. I).1 
MeO OMe 
œ.COOH r Me 
S H 
OEt 
H ii Me-
C f c ^ 
Figure 1 
The frequent occurrence of the isoquinoline nucleus in alkaloids and in some 
physiologically active compounds has led to considerable interest in the synthesis of variously 
fuctionalized and saturated isoquinoline derivatives.24 Asymmetric methods have also been 
developed for the preparation of enantiomerically pure derivatives 5 
The synthesis and transformations of 1,2,3,4-tetrahydroisoquinoline derivatives have 
been a research topic at the Institute of Pharmaceutical Chemistry, University of Szeged, in 
recent decades. During this work, numerous tetrahydroisoquinoline 1,2- and 1,3-amino 
alcohols (7 and 8) have been prepared and cyclized to the corresponding tetrahydroiso-
2 
quirioline-condensed five- and six-membered 1,3- and 1,2,3-heterocycles (9 and 10) (Fig. 2). The 
conformations of the prepared tricycles were found to be strongly influenced by the steric 
effects of the substituents and the configurations of the substituted atoms. Some of the 
prepared derivatives proved to possess valuable pharmacological properties (e.g. 
antihypertensive, antiarrhythmic and antihypoxic effects).6-15 
7 8 9 
R1 = H, OMe, OEt; R2 = H, Me, Ph, CH2OH; R3 = H, Ci-Q-alkyl; Ph; R4 = H, Me; 
R5, R6 = H2; O; N-aryl; H, aryl; R7, R8 = H2; O; N-aryl; H, aryl; 0 2 ; O, electron pair; 
O, CI; O, Ph; O, N(CH2CH2C1)2; X = C,S,P; Y = 0 , S ; n = 1,2,3, 4,5 
Figure 2 
The aim of my PhD work was to study tetrahydroisoquinoline 1,2- and 1,3-diamines 
(11-13) and tetrahydroisoquinoline 1,2-hydrazino alcohols (14 and 15), which are the aza 
analogues of the previously investigated tetrahydroisoquinoline amino alcohols (Fig. 3). We 
planned to devise convenient synthetic methods for the preparation of variously substituted 
derivatives, and to study the synthetic applicabilities of 11-15 in cyclization reactions with a 
view to obtaining isoquinoline-condensed heterocycles. 
f Y Y n N H 2 
NH 
11 12 13 
14 15 
R1 = H, Me; R2 = H, Me; R3 = H, Me, Ph; R4 = H,OMe 
Figure 3 
The aim of these transformations was to collect data relating to the scope and 
limitations of the effects influencing the steric structure and the ring-chain tautomeric character 
3 
of the isoquinoline-condensed, saturated 1,3- and 1,2,3-heterocycles. The synthesis of certain 
diamine derivatives for pharmacological studies was also planned. 
Details of the syntheses, physical and analytical data on the new compounds described 
in the thesis, and descriptions of the NMR spectroscopic analyses of the tautomeric equilibria 
are to be found in the experimental part of the enclosed publications. 
The references to the publications relating to my own research are given as Roman 
numerals; other literature references are given as Arabic numerals as superscripts. 
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2. LITERATURE 
In the literature part of my PhD thesis, I would like to summarize the most important 
synthetic methods and transformations of 1-aminoalkyltetrahydroisoquinolines. To collect 
chemical information related to the subject, the SciFinder and Beilstein databases were used. 
Due to the limited size of the thesis, data on the chemistry and the various synthetic 
applications of 1-aminoaryltetrahydroisoquinolines16-18 are omitted from this compilation. 
2.1. Synthesis ofl-aminoalkyltetrahydroisoquinolines 
The synthesis of 1-aminoalkyl-substituted 1,2,3,4-tetrahydroisoquinolines is of interest 
since this moiety can be found in natural compounds such as amphibin I (16), and saframycins 
(17 and 18). The natural amphibin I (16), the alkaloid of Ziziphus amphibia, A. Cheval, is a 
mixture of two diamine diastereomers, one of which has the 1R,9S and the other the 1S,9R 
configuration (the valine in the side-chain has the S configuration in both isomers).19 
Saframycins (17 and 18) are naturally-occurring antiproliferative agents which have been 
isolated from bacterial sources (e.g. Streptomyces lavendulae) and marine sponges.20 The 
syntheses of these bisquinone alkaloids could be accomplished through tetrahydroisoquinoline 
intermediates. 
The main synthetic methods that have been applied for the preparation of 1-
aminoalkyl-substituted 1,2,3,4-tetrahydroisoquinolines can be classified according to the 
sequence of the formation of the amino functional group and the isoquinoline ring. Reduction 
methods involve constructions of the amino group from the corresponding nitrile, 
carboxamide, azide or nitro derivatives of differently saturated isoquinolines. In some cases, 
the amino function is built into the side-chain by the substitution of an appropriate leaving 
OMe 
amphibin 1:16 Me 
X = CN: saframycin A: 17 
X = H: saframycin B: 18 
Figure 4 
5 
group. In the methods based on isoquinoline ring construction through the use of amino-
containing building blocks, the BlSCHLER-NAPlERALSKI and the PlCTET-SPENGLER cyclizations 
are applied, starting from the corresponding amino acids or amino aldehydes. 
2.1.1. Reductions of isoquinoline-l-carboxylic acid derivatives 
Through the reductions of /V-containing derivatives of tetrahydroisoquinoline amino 
acids (nitriles or amides), the corresponding diamines could be obtained. Amides are usually 
reduced with LiAlPU, while nitriles can be reduced by using hydrogen developed during 
alcoholate formation with Na21-22 by catalytic hydrogenation23 or by using LÍAIH424 as a 
reducing agent. Starting from substituted carboxamides, N-substituted diamines could be 
obtained.25'26 
JONES et al. accomplished the synthesis of diamine 23 via an amide intermediate, 
starting from the REISSERT compound of sulfonamide type 19. By reduction with NaBTLt, 
dihydroisoquinoline 19 was converted into 1-isoquinolinecarbonitrile (20), which was hydro-
lysed to the carboxamide 21. Catalytic reduction of the pyridine ring of 21 resulted in tetra-
hydroisoquinoline 22, the carboxamide substituent of which was converted to the 
corresponding aminomethyl group by using diborane generated in situ (Scheme l).27 
CN 
19 
CN 
23 22 21 
Reagents and conditions: (i): NaBFL», EtOH, r.t, 2 h, 100%; (it): KOH, H2O2, 40 °C, then r.t, 
1.5 h, 82%; (in): PtOz, H2,70% EtOH, HBr, 20 atm, r.t, 2 h, 95%; (iv): BFj.OEtj, NaBHt, THF, 
0 °C, 20 min, reflux, 12 h, 100%; (v): 50% NaOH, 100 °C, 8 min, 95%; (vi): 1. HBr, QH 6 , 10 
min, 97%; 2. PtCk H2, 70% EtOH, 3 atm, 78%; (vii): UAIH4, THF, reflux, 8 h, 30%. 
Scheme 1 
KATZ and POPP converted amide 21, obtained directly from the REISSERT compound 19 
by alkaline treatment, to diamine 23 by sequential reductions of the aromatic ring and the 
carboxamide function.28 
6 
Reductive ring-opening of isoquinoline-condensed cyclic carboxamides may lead to 
tetrahydroisoquinoline diamines. When BEGLEY and WHTTTAKER reduced the quaternary 1,4-
diazepino[7,l-fl]isoquinolin-2-one derivative 26, obtained by a SCHMIDT rearrangement and a 
subsequent quaternization, starting from benzo[a]quinolizin-2-one 24, with Red-Al, they foimd 
that the initial reduction of the amide function was followed by a HOFMANN elimination. 
© 
24 25 
28 29 
H 
N ^ E t 
Me 
Reagents and conditions: (i): NaN3, H2S04, 0 °C, then 24, CHCI3, 90%; (ii): Mel, AcOH, reflux, 
1 h, 98.5%; (in): Red-Al, THF, reflux, 2.5 h. 
Scheme 2 
The enamine intermediate 27 was reduced further to l-(2-aminoethyl)-2-methyl-l,2,3,4-
tetrahydroisoquinoline (28) as the major, and its N-(2-butyl)-substituted derivative 29 as the 
minor product. Compounds 28 and 29 were separated by fractional crystallization and 
chromatographic methods (Scheme 2).29 
To examine their (^-adrenoceptor activity, BEAUMONT et al. synthetized the 
catecholamine analogue l-(aminomethyl)tetrahydroisoquino!ines by starting from 2-
substituted l-cyano-l,2,3,4-tetrahydroisoquinoline derivatives (30). While the N-methyl and the 
N-benzyl-substituted compounds (30, R = Me, CH2Ph) could be conveniently reduced to the 
corresponding N-substituted diamines (31 and 3 3 ) , ^ in an attempt to perform a similar 
transformation for the N-unsubstituted derivative (30, R = H), HCN elimination occurred and 
1,2,3,4-tetrahydroisoquinoline (32) was obtained as the main product.31 
The N-benzyl-substituted diamine could be applied both for the preparation of the N-
unsubstituted diamine 23 (debenzylation) and for the synthesis of the isoproterenol analogue 
34 (reductive alkylation prior to debenzylation) (Scheme 3).31 
7 
(i) 
R = Me 
( ¡ 0 
(9 
R = H 
R = CH2Ph 
NH 
32 
(Hi) 
NH/Pr 
34 
(iv) 
Reagents and conditions: (i): LiAlHLt; (ii): A1H3, Et20, r.t., overnight, 88%; (Hi): 1. NaBH3CN, 
HQ, MeOH, acetone, r.t., 16 h, 97%; 2. 5% Pd/C, H2, 96% EtOH, HC1, 55%; (iv): Pd/C, H2, 
96% EtOH, 1 atm, r.t, 24 h, then 50 °C, 12 h, 93%. 
Scheme 3 
2.2.2. Reductions ofl-nitroalkyl- or 1-azidoalkyl-substituted isoquinolines 
Nitro and azido functions can be conveniently reduced to the corresponding amines 
and these reactions have been utilized in the preparation of N-substituted 
tetrahydroisoquinoline 1,2-diamines. 
In 1925, HAWORTH and PERKIN tried to reduce the readily available 1-nitromethyl-
tetrahydroisoquinolines, but their attempts were reported to be unsuccessful, resulting in the 
elimination of nitromethane with a variety of reducing agents (e.g. Zn, SnCb and Na-Hg).32 
When BEAUMONT et al. investigated the LiAlFLj reduction of the analogous 2-benzyl-6,7-
dimethoxy-l-(nitromethyl)tetrahydroisoquinoline (36), they observed that the reaction 
conditions had a great influence on the yield. 
35 36 37 
Reagents and conditions: (i): CH3NO2, KOH, MeOH, r.t., 1 h, 84%; (ii): 1. LiAlH», THF, reflux, 
1 h, 16% (in a SOXHLET thimble: 85%); or 2. Red-Al, benzene, reflux, 1 h, 25%. 
Scheme 4 
When a "normal addition" procedure was applied (i.e. addition of a THF solution of 36 to a 
stirred suspension of UAIH4 in THF), the yield was only 16%, but when a solution of 36 in THF 
was refluxed beneath a SOXHLET thimble containing UAIH4 (i.e. a "reverse addition"), a 
dramatic increase in the yield (to 85%) was achieved (Scheme 4).31 
8 
Tetrahydroisoquinoline diamine 40 proved to be a key intermediate in the synthesis of 
an oxorhenium(V) complex (41) mimic of a steroidal oestrogen. Compound 40 was prepared by 
a transformation of the hydroxy function of the corresponding amino alcohol analogue 38. 
Treatment of 38 with diphenylphosphoryl azide under MlTSUNOBU conditions resulted in the 
azide 39, which was hydrogenated in the presence of Pd catalyst to the amine 40. The syn and 
anti isomers of the tetradentate oxorhenium(V) complex 41 were separated by flash 
chromatography and both of them proved to exhibit a higher lipophilicity than that of 
oestrogen, while they bound only weakly to the oestrogen receptor (Scheme 5).33 
41a: Ha; 41b: Hp 
Reagents and conditions: (i): (Ph)jP, DEAD, THF, 0 °C, 15 min, then 38, (PhO)2PON3, r.t, 
12 h, 91%; (ii): 10% Pd/C, EtOH, H2, r.t., 21 h, 84%. 
Scheme 5 
2.1.3. Substitutions in the side-chain by nitrogen-containing nucleophiles 
I shall now discuss the substitution reactions of l-(haloalkyl)- or l-(hydroxyl)-
substituted isoquinoline derivatives with the appropriate N-contairung agents, when no further 
transformation or only a hydrolytic step (but no reduction) is required to construct the amino 
function in the side-chain. 
In consequence of the activated leaving group at the a-position of the side-chain, l-(a-
haloalkyl)-3,4-dihydroisoquinolines are convenient starting materials for nucleophilic 
substitutions with amines to yield di- or tetrahydroisoquinoline diamines. The substitution 
reactions of l-(chloromethyl)-3,4-dihydroisoquinoline (42) with acyclic or cyclic primary or 
secondary amines gave diamines 43 in good yields, which were then reduced to the 
corresponding tetrahydro derivatives 44 with NaBHt. Some of the N-arylacetylated diamines 
45 proved to exhibit K opioid analgesic activities. The pyrrolidine derivative with the S 
9 
configuration (46) had a 100-fold higher K receptor-binding affinity than that of morphine 
(Scheme Ô).34 
R1, R2 = H, Me, Et, nPr, -(CH2)4-, -(CH2)5-; Ar = 2-NCb-Ph, 3-NCb-Ph, 
4-N02-Ph, 4-Br-Ph, 4-CF3-Ph, 3,4-Ck-Ph 
Reagents and conditions: (i): NHRtR2, MeOH, 0 °C, then r.t., overnight; (ii): NaBH,, MeOH, 
0 °C, 2 h, 46-80% (i+ii); (in): ArCH2COCl, K2CO3, CH2CL2,0 °C, 3 h. 
Scheme 6 
The above methodology was successfully applied by GRIFFITH et al. in the 
transformations of l-(chloromethyl)-4-phenyl-3,4-dihydroisoquinoline. By nucleophilic 
substitution with primary or secondary amines, 4-phenyl-substituted analogues of 43 were 
obtained, which were reduced to the corresponding tetrahydro derivatives. Due to the 4-
phenyl substituents, cis and trans isomers were formed, which were readily separated by 
fractional crystallization. The catalytic hydrogénation proved to be highly selective (cis : trans = 
~10 :1) for the formation of the cis isomer.35-37 
The total synthesis of the antitumour antibiotic saframycin B (18) could be 
accomplished via a tetrahydroisoquinoline diamine intermediate (49), which was obtained 
from a l-(hydroxymethyl)-substituted tetrahydroisoquinoline derivative (47) under 
MlTSUNOBU conditions. When 47 was treated with diethylazodicarboxylate (DEAD), triphenyl-
phosphine and phthalimide, phthalimidomethyl-substituted compound 48 was obtained, the 
phthaloyl group of which was removed by hydrolysis with hydrazine hydrate. Diamine 49 was 
converted in two steps to racemic saframycin B (18) (Scheme T).38"39 
42 43 44 
10 
18 49 
Reagents and conditions: (i): DEAD, PhthNH, PPh3, THF, r.t, 100%; (ti): H2NNH2.H20, 
EtOH, reflux, 90%. 
Scheme 7 
2.1.4. Methods based on the BlSCHLER-NAPIERALSKl ring-closures of amino acid derivatives 
Probably the method most frequently used for the synthesis of isoquinolines is the 
BlSCHLER-NAPIERALSKl reaction, which consists in the cyclodehydration of N-acyl derivatives 
of (3-phenylethylamines with LEWIS acids such as POCI3 or P2O5 pentoxide and affords 3,4-
dihydroisoquinolines. Starting from (3-phenylethylamides of amino acid derivatives bearing an 
appropriate protecting group on the basic nitrogen, l-(aminoalkyl)-substituted 3,4-
tetrahydroisoquinolines could be obtained, the reduction (and N-deprotection) of which results 
in tetrahydroisoquinoline diamines. 
This method was first applied for the synthesis of a tetrahydroisoquinoline 1,2-diamine 
(11) by HARWOOD and JOHNSON in 1933. The amide 52, obtained from the N-phthaloylglycyl 
chloride and homoveratrylamine, was cyclized with POCI3 in toluene to yield 
dihydroisoquinoline 53. The double bond of 53 was reduced by catalytic hydrogénation and 
the phthaloyl protecting group of 54 was removed by hydrazinolysis (Scheme 8).40 Ring-closure 
of the phenyl analogue of 52, without the activating methoxy groups, proceeded with a 
considerably lower yield.41 
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HOOC 
50 
(ii) 
MeO 
MeO 
M 
M e 0 ^ 0 H N Y ° 
52 
(Hi) 
7 
NH, 
11 
54 53 
Reagents and conditions: ft): SOCI2, 77%; (ii): homoveratrylamine, Na2C03, 72%; (ni): POCI3, 
toluene, reflux, 1.5 h, 87%; (iv): PtO^ Ha, 3 atm; (v): H2NNH2.H20, EtOH. 
Scheme 8 
N-Phthaloylamino carboxamides of type 52, the starting materials for the BLSCHLER-
NAPIERALSKI cyclization, can alternatively be obtained by the N-alkylation of potassium 
phthalimide with the corresponding N-chloroalkanoyl p-phenylethylamines42^4 
HOOC o 
Me^N-^C 
o ^ O 
55 
(i) 
56 
0 
57a 57b 
Reagents and conditions: ft): 1. homoveratrylamine, /V-hydroxysuccinimide, DCC, CHCb, 
20 °C, 12 h, 94%; 2. P2Os, CHCI3, -30 °C, then 0 °C, 24 h, 85%; (ii): NaBHjCN, HQ, MeOH, 
r.t, 30 min., 67% (57a), 16% (57b). 
Scheme 10 
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BlSCHLER-NAPIERALSKI ring-closure of the amide obtained from N-phthaloyl-L-alanine 
(55) and homoveratrylamine was applied in the preparation of amphibin I (16) by TSCHESCHE et 
al. The NaBHhCN reduction of the dihydroisoquinoline 56 resulted in a 4 : 1 mixture of the 
diastereomers 57a and 57b, which were separated by chromatographic methods. Considerable 
racemization of the chirality centre of L-alanine could be avoided when a rapid reduction and 
work-up were employed immediately after ring-closure. Compounds 57a and 57b were 
converted in four steps to (1S,9R)- and (lR,9S)-amphibin I (16) (Scheme 9).19 
2.1.5. PlCTET-SPENGLER cyclizations by using amino aldehydes 
The PlCTET-SPENGLER reaction is a condensation of p-phenylethylamines with carbonyl 
compounds in the presence of an acidic catalyst to give 1,2,3,4-tetrahydroisoquinolines. By 
choosing an appropriate carbonyl component, such as an N-protected amino aldehyde, this 
method can be utilized for the synthesis of tetrahydroisoquinoline diamines. 
Condensation of racemic N-phthaloyl alaninal (58) with dopamine hydrochloride in 
methanol resulted in a diastereomeric mixture of tetrahydroisoquinolines (59), which were O-
methylated with diazomethane and then N-methylated by using ESCHWEILER-CLARKE 
conditions. Diastereomers of 60, separated by preparative thin-layer chromatography, were 
converted to diamine diastereomers 61 and 62 by hydrazinolysis of the phthaloyl moiety. 
61 62 
Reagents and conditions: (i): dopamine hydrochloride, MeOH, Ar, r.t., 7 days, 37%; 
(ii): 1. CH2N2; 2. HCHO, HCOOH; (iii): 1. preparative thin-layer chromatography; 
2. H2NNH2.H2O. 
Scheme 10 
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Diamines 61 and 62 were resolved by using di-(p-toluyl)-L- or -D-tartaric acid, and all of the 
possible stereoisomers of amphibin I (16) were synthetized from the four diamine enantiomers 
(Scheme 10).46 
The PlCTET-SPENGLER reaction of the N-Fmoc-protected L-alaninal and L-DOPA 
hydrochloride gave l-aminomethyl-a-methyl-l,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
diastereomers, the 1S,3S,1'S isomer of which proved to be a good (3-turn dipeptide mimetic.46 
CHO 
r^NHFrnoc oMe N 
M e C V S + 
• V t Me y OTBS 
OMe 
NHFmoc 
Reagents and conditions: (i): 1. Na2S04, CH2CI2, r.t., >90%; 2. LiBr, DME, 35 °C, 65-72%; (ii): 1. 
CH20-H20, NaBH(OAc)3, MeCN, r.t., 94%; 2. AcOH, TBAF, THF, r.t.; 3. DBU, CH2Cl2, r.t., 
92%; (iii): N-Fmoc-glycinal, Na2S04, CH2Cl2, r.t, 66%; (iv): ZnCl^ MesSiCN, CF3CH2OH-
THF, r.t, 86%; (v): 1. DBU, CHjCfe, r.t, 88%; 2. ClCOCOCH3, PhNEfc, CH2Cl2, 0 °C, 89%; 3. 
PhIO, MeCN-H20,0 °C, 66%. 
Scheme 10 
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MYERS and KUNG described a short and enantioselective synthetic route to tine potent 
antitumour agent (-)-saframycin A (17) with tetrahydroisoquinoline diamine intermediates 
obtained by PlCTET-SPENGLER cyclization. In the first step, the enantiomerically pure N- and C-
protected a-amino-aldehydes (63 and 64, respectively) were condensed to give the cis-
tetrahydroisoquinoline (65) as the main product (a 5 : 1 mixture of the cis and trans isomers was 
formed, which was separated by flash chromatography). By N-methylation and removal of the 
N-Fmoc protecting group of 65, a tetrahydroisoquinoline diamine (66) was obtained, the 
PlCTET-SPENGLER cyclization of which with N-Fmoc-glycinal was accomplished with good cis-
selectivity to yield 67. Compound 67 was converted to the pentacyclic intermediate 68, which 
was transformed in three steps to (-)-saframycin A (17) (Scheme ll).47 
The MYERS group devised a solid-phase version of the above procedure, which proved 
to be suitable for the preparation of a great number of saframycin analogues with wide-ranging 
structural diversity.48-49 
By PlCTET-SPENGLER cyclizations of N-arylsulfonyl-J3-phenylethylamines and 3-
(phthaloylamino)propanal and subsequent removal of the phthaloyl group, BARN et al. 
prepared l-(2-aminoethyl)-2-arylsulfonyl-l,2A4-tetrahydroisoqxiinolines, by N-acylations of 
which tetrahydroisoquinoline sulphonamide-based libraries were synthetized both in solution 
and in the solid phase. Some of the prepared compounds exhibited 5-opioid receptor 
activity.50-51 
2.2. Transformations of tetrahydroisoquinoline diamines 
Although the diamine function provides various possibilities for further 
transformations, including N-substitution reactions, tetrahydroisoquinoline diamines are 
applied almost entirely for the synthesis of isoquinoline-condensed heterocycles. By insertion 
of a one-carbon-containing unit, imidazo[5,l-«]- and pyrimido[6,l-a]isoquinolines are obtained. 
Tetrahydroisoquinoline 1,2-diamines have been used as the starting materials for the synthesis 
of pyrazino[2,l-fl]isoquinoline derivatives. There are some examples of the conversion of 
tetrahydroisoquinoline 1,3-diamines to steroidal analogues containing nitrogens at positions 8 
and 13 of the gonane skeleton (8,13-diazasteroids). Some heterocyclic derivatives of 
tetrahydroisoquinoline diamines proved to possess biological activities. 
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2.2.1. Imidazo[5,l-a]- and pyrimido[6,l-a]isoquinolines 
Depending on the one-carbon-containing unit inserted between the amino groups of 
tetrahydroisoquinoline diamines, various derivatives of imidazo[5,l-a]- and pyrimido[6,1-a]iso-
quinolines can be obtained. 
Ring-closures of 23 and 69 with imidate (for n = 1) or orthoester (for n = 2) result in 
cyclic amidine derivatives 71a,b, respectively.27-52 The LiAlTh reduction of 3-methyl-l,5,6,10b-
tetrahydroimidazo[5,l-a]isoquinoline (71a) led not to the expected imidazolidine derivative, 
but to the l-(ethylaminomethyl)-l,2,3,4-tetrahydroisoquinoline 72 (Scheme 12),27 which can be 
explained by the ring-chain tautomeric character of the imidazolidine intermediate. 
In the reactions of tetrahydroisoquinoline diamines 23 and 69 with carbon disulfide, 
dithiocarbamate salts are formed, which are converted to the corresponding cyclic thiourea 
derivatives 73a,b on prolonged heating. S-Alkylation of l,5,6,10b-tetrahydroimidazo[5,l-fl]iso-
quinoline-3(2H)-thione (73a) with chloroacetic acid yielded an isothiuronium salt intermediate, 
hydrolysis of which afforded the cyclic urea 74a.28 The analogous cyclic urea of 
pyrimidoisoquinoline of type 74b was obtained by treatment of 70 with diethyl carbonate in 
the presence of NaOEt (Scheme 12).53 
'n 1 
74a,b 72 
R = H, n - 1: 23; R = H, n = 2: 69; R = OMe, n = 2: 70; n = 1: 71a; n = 2: 71b; 
n = 1: 73a; n = 2:73b; R = H, n = 1: 74a; R = OMe, n = 2: 74b 
Reagents and conditions: (i): ethyl acetimidate hydrochloride, EtOH, reflux, 3 h, 66%; (ii): 
triethyl orthoacetate, BuOH, reflux, 15 h, 71%; (Hi): LiAlH,, THF, reflux, 30 min, 86%; (iv): 
1. CS2, NH4OH, 50% EtOH, reflux, 4 h, then HC1, reflux, 18 h, 72%; (v): CS2, EtOH, r.t., 
1.5 h, then DMF, reflux, 40 min, 95%; (vi): 1: CICH2COOH, H 20, reflux, 3 h, 99%; Z 
NH4OH, H20,95%; (vii): (EtO)2CO, NaOEt, EtOH, reflux, 4 h, 64%. 
Scheme 10 
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On cyclization of l-(aminomethyl)-l,2,3,4-tetrahydroisoquinoline (24) with bis(alkoxy-
carbonyl) derivatives of 2-methyl-2-thiopseudourea, 3-[(alkoxycarbonyl)amino]-l,5,6,10b-tetra-
hydroimidazo[5,l-a]isoquinolines were prepared.54 
There is an example of the aldehyde ring-closure of a tetrahydroisoquinoline diamine 
(cyclic aminal formation): treatment of l-[(phenylamino)methyl]-6,7-dimethoxy-l,2,3,4-tetra-
hydroisoquinoline with formaldehyde resulted in 8,9-dimethoxy-3-phenyl-l,2,3,5,6,10b-hexa-
hydroimidazofSd-aJisoquinoline.25 
2.2.2. Pyrazino[2,l-a]- and l,4r-diazeyino[7,l-a]isocjuinolines 
Cyclization of tetrahydroisoquinoline diamines with difunctional compounds (e.g. 
olefinic esters, haloalkylcarboxylic acid chlorides or diesters) results in pyrazino[2,l-fl]- or 1,4-
diazepino[7,l-fl]isoquinolines. Since tetrahydroisoquinoline diamines contain non-equivalent 
nitrogens, when cyclizing agents containing two different functional groups are used, 
regioisomeric products are formed. To avoid the formation of regioisomers, N-protecting 
groups should be applied.25 
When SHEKHTER et al. reacted the diamine 75 (R1 = R2 = H) with diethyl fumarate for the 
purpose of synthetizing praziquantel analogues, formation of the regiosomeric pyrazino[2,l-a]-
isoquinolines (76 : 77 = 3 : 2) was observed. The regioisomers were separated by fractional 
crystallization of their hydrochlorides. No concerning the relative configurations of 76 and 77 
were reported (Scheme 13).55 
R2 
78 79 
Reagents and conditions: (i): diethyl fumarate, EtOH, r.t, 48h, 45% (71), 32% (72); (ii): diethyl 
oxalate, CHC13, reflux, 4h, 77%; (iii): BH3, THF, reflux, 3h, 89%. 
Scheme 10 
47 
The ring-closure of ds-l-(methylamino)methyl-4-phenyl-l,2/3/4-tetrahydroisoquinoline 
(75, R1 = Me, R2 = Ph) with diethyl oxalate in refluxing CHCI3 gave the cyclic diamide 78. 
Compound 78 was conveniently reduced with BH3 to give the mianserin analogue pyrazino-
[2,1-ajisoquinoline 79, which was resolved with dibenzoyltartaric acid. In pharmacological 
evaluations, racemic 79 proved to possess excellent atypical antidepressant activity, which 
resides predominantly in the (+) isomer, while the (-) isomer was found to have antihistamine 
activity.35 
2.2.3. 8,13-Diazasteroids 
The synthesis of steroid derivatives containing nitrogen atoms in various positions of 
the carbocyclic skeleton has gained wide attention in recent decades. The modified steroids 
containing nitrogen atoms in the carbocyclic skeleton are interesting compounds from a phar-
macological aspect. Some 4-, 8- and 15-aza derivatives proved to exhibit antifungal activity, 
and 4-azasteroids (e.g. finasteride) have effects against benign prostatic hypertrophy.56"58 
Tetrahydroisoquinoline diamines and their N-succinyl or N-phthaloyl intermediates are 
good starting materials for the preparation of diazasteroid derivatives. Catalytic hydrogénation 
of 6,7-substituted l-(2-succinylaminoethyl)-3,4-dihydroisoquinolines (80) over Pt02 resulted in 
8,13-diazaoestrone derivatives 81 via a hemiaminal intermediate, 59"61 By reduction of the 
carboxamide function with LiAlTb, 8,13-diazaoestrane derivatives 82 were obtained (Scheme 
14; instead of the classical "steroidal" structures, azasteroids are depicted in the schemes in 
accordance with the drawings of tetrahydroisoquinoline diamines applied in the thesis). 
During the pharmacological tests, compounds 81 and 82 exhibited analgesic activity. 
u 82 
81 
R1 , R2 = H, Me, CI, OMe, OCH2Ph 
Reagents and conditions: (i): Pt02, H2, MeOH, r.t, 12 h, 69-76%; (ii): LiAlH», THF, reflux, 
66 h, 80%. 
Scheme 14 
The 8,13-diazaoestrane derivative 82 (R1 = R2 = OMe) was also prepared by reductive 
cyclizations of l-[2-(3-oxo-l-pyrrolidinyl)ethyl]-l,2,3,4-tetrahydroisoquinoline. Through the use 
of a bulky reducing agent, LiAlH[OCH(CH3)fBu]3, formation of uncyclized by-products could 
49 
be diminished.62 The reductive cyclization method was successfully applied in the case of l-(2-
phthaloylaminoethyl)-3,4-dihydroisoquinolines to yield 8,13-diazaoestrone derivatives 
containing a benzene ring attached to ring D of the steroidal skeleton.63 
In the previous cases, the protecting groups of the nitrogen were built into the newly 
formed heterosteroid. Tetrahydroisoquinoline diamines can be converted to diazasteroid 
derivatives by domino ring-closures with difunctional reagents. This strategy was applied for 
the cyclizations of the diamine 83 with 3-ethoxycarbonylpropionimidate or with y-oxo-acids, 
when 8,13-diazaoestrone derivatives (84 and 85) were formed (Scheme 15) ,23 64 The ring-closure 
with y-oxo-acids took place via ring-chain tautomeric pyrimido[6,l-a]isoquinoline inter-
mediates, resulting in tetracycles 85 with excellent diastereoselectiviti.es (Scheme 15). 
R1 = H, OMe; R2 = Me,Ph, 
Reagents and conditions: (i): 1. 3-ethoxycarbonylpropionimidate hydrochloride, 0 °C; 
2. HC104; (ii): RCO(CH2)2COOH, toluene, reflux, 1-2 h, 70-74%. 
Scheme 15 
Inhibition of the synthesis of the fungal ergosterol causes serious malfunctions of the 
cell membrane, inhibition of the fungal growth, and cell death. Certain enzymes involved in 
ergosterol biosynthesis create carbocationic high-energy intermediates (HEIs). Compounds 
with structures similar to those of HEIs [i.e. high-energy intermediate analogues (HEIAs)], are 
able to act as inhibitors of fungal enzymes. GOflNITZER et al. prepared some 8,13,15-
triazasteroids and their 13,17-seco derivatives for the purpose of finding potential HEIAs as 
antifungal compounds. 
86a-c 87a-c 88a-c R2 
R1 = H: a; R i = O H : b ; R3 = OMe:c 
Reagents and conditions: (i): 1. CS2, EtOH, r.t., 1.5 h, then DMF, reflux, 40 min; 2. Mel, 
MeOH, reflux, 1 h, 86% (87a), 49% (87b), 73% (87c); (ii): R2(CH2)2NH2, THF, reflux, 12-16 h, 
80-91%. 
Scheme 16 
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Treatment of the l-((3-aminoethyl)tetrahydroisoquinolines 86a-c with CS2 and sub-
sequent methylation of the cyclic thiourea intermediates with methyl iodide gave the iso-
thiuronium salts 87a-c. When 87a-c were reacted with alkyl- and alkenylamines, the N4-
substituted 4-iminopyrimido[4,3-a]isoquinolines (88a-c) were formed, which proved to be 
HEIAs with the structure of 8,13,15-triaza-13,17-secosteroids (Scheme 16). Compounds 88a and 
88c, each with a saturated 3,7-dimethyl-branched octyl side chain, displayed the best inhibitory 
effects against the tested fungi. The inhibitory efficacy was better against yeasts and 
dermatophytes than that against the mould species.44'6566 
HEIAs with 8,13,15-triazasteroid structure were synthetized by transformations of the 
substitution of 87a. On reaction with aminoalkanols, N4-hydroxyalkyl-substituted 4-imino-
pyrimido[4,3-a]isoquinolines (89a-c) were formed, the hydroxy —* bromo substitution of which 
was performed by using PBr3. Intramolecular cyclizations of 90a-c furnished the 8,13,15-
triazasteroids 91a-c (Scheme 17).67 
R = H: a; R = hexyl: b; R = 1,5-dimethylhexyl: c 
Reagents and conditions: (i): 2-aminoethanol (a), l-amino-2-octanol (b), l-amino-3,7-
dimethyl-2-octanol (c), respectively, MeCN, reflux, 14-16 h, 71-87%; (ii): PBr3, CH2CI2, 
-10 °C, lh, then r.t., 15 h, 64-100%; (iii): 1. NaH, THF, -10 °C, 1 h, then r.t., 20 h; 2. treatment 
with ethanolic HQ, 30-70%. 
Scheme 17 
2.2.4. Other heterocycles 
There are two examples when the ring-closure of a tetra- or dihydroisoquionoline 
diamine is directed toward the benzene ring by the lack of a substitutable hydrogen at the 
isoquinoline-nitrogen. 
In the reaction of the N-tosylated diamine 92 with formaldehyde, the benzo[d,e][l,7]-
naphthyridine derivative 93 was formed, the tosyl group of which was removed by using Na in 
liquid NH3 (Scheme 18).68 
When the phenolic l-(2-aminoethyl)-3,4-dihydroisoquinoline derivative 95 was treated 
with peroxosulfate bisdemethyl-aaptamine (96) was obtained by oxidative cyclization besides 
minor amounts of its oxidation product 97. Aaptamines are marine alkaloids with a 1H-
benzo[d,e][l,6]naphthyridine structure and interesting biological properties, such as 
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antitumour and cardiac activity. The mild conditions of the ring-closure support the idea that 
the biosynthesis of the aaptamines may follow a similar course (Scheme 18).69 
Me<X MeCU MeOv 
,NTos " » . . NTos ( l i ) » 
MeO MeO 
92 
MeO 
95 
HN. 
96 
N 
HC1 
Reagents and conditions: (i): 2 N HC1, 37% HCHO, 100 °C, 45 min, then r.t., 12 h, 65%; (ii): 
NHs, Na, THF, 61%; (iii): 1.1% KOH, K2S2O8, r.t., 2 h; 2. HC1,49% (96), 6% (97). 
Scheme 18 
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3. RESULTS AND DISCUSSION 
During my experimental work, tetrahydroisoquinoline diamines and hydrazino 
alcohols were prepared. By ring-closures of these difunctional compounds, isoquinoline-
condensed, saturated 1,3- and 1,2,3-heterocycles were produced and their conformational and 
ring-chain tautomeric equilibria were investigated. 
3.1. Synthesis of difunctional compounds 
3.1.1. Synthesis of tetrahydroisoquinoline diamines 
For the preparation of l-(arrunomethyl)-6,7-dimethoxy-l,2,3,4-tetrahydroisoquinoline 
11, the synthetic method using an N-protected amino acid as starting material was chosen. The 
protecting group was the carbobenzyloxy (Cbz) group, which is a protecting group often used 
in peptide chemistry. The N-Cbz-glycine 98 and homoveratrylamine were coupled via the 
mixed anhydride method. BlSCHLER-NAPIERALSKl ring-closure of carboxamide 99 resulted in 
dihydroisoquinoline 100, which was reduced with NaBFL to yield tetrahydroisoquinoline 101. 
101 Was deprotected by treatment with 33% HBr in acetic acid (Scheme 19).1 
MeOv 
COOH < 
NHCbz 
98 
0) T Y ^ 
MeCk 
(H) M e O ^ j Q 
M e 0 s A ^ i 
J A J L ^ N H MeO 
CbzHN 
99 
(iv) 
NHCbz 
100 
NH2 
11 
Reagents and conditions: (i): 1. CICOOEt, EtjN, toluene, -10 °C, 5 min.; 2. homo-
veratrylamine, CH2CI2, 0 °C, then reflux. 5 min., 62%; (li): POCI3, CHCh, reflux, 3 h, 71%; 
(Hi): NaBHt, MeOH, 0 °C, 3h, then r.t, 3 h, 83%; (iv): 1. HBr, AcOH, r.t., 30 min.; 2. NaOH, 
78% (1+2). 
Scheme 19 
The l-(2'-aminoethyl)-6,7-dimethoxy-l,2,3,4-tetrahydroisoquinolines 106a-e were 
prepared in five steps, similarly to the l-(aminomethyl)-substituted analogues, starting from 
the corresponding N-Cbz-protected |3-alanines 102a-c and homoveratrylamine. p-Alanine 
derivatives 102b and 102c were obtained by transformations of ethyl 3-anilinopropanoate70 and 
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ethyl 3-amino-2-methyl-propanoate71/ respectively. Reduction of urethane 105a with LiAlH4 
produced the N-methyl-substituted diamine 106c (Scheme 20). 
MeO 
R 
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COOH 
NR2Cbz 
102a-c 
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MeO 2 HBr 
(iv) 
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103a-c 
MeO 
MeO 
NR2Cbz 
M e O - C O n 2HCI 
k^.NHMe 
106a,b 105a,b 106c 
102-104: R1, R2 = H: a; R1 = H, R2 = Ph: b; R1 = Me, R2 = H: c; 105-106: R2 = H: a, R2 = Ph: b 
Reagents and conditions: (i): 1. CICOOEt, Et3N, toluene, -10 °C, 5 min.; 2. homo-
veratrylamine, CH2CI2, 0 °C, then reflux, 5 min., 64-91%; (ii): POCI3, ŒCI3, reflux, 3 h, 65-
88%; (ni): NaBH4, MeOH, 0 °C, 3 h, then r.t., 3 h, 82% (105a), 94% (105b); (iv): HBr, AcOH, 
r.t., 30 min., 74% (106a), 78% (106b); (v): 1. UAIH4, THF, reflux, 3 h; 2. HC1, 83% (1+2). 
Scheme 20 
In the transformations of dihydroisoquinoline 104c, the reducing agent applied and the 
sequence of the reduction and deprotection steps proved to have marked effects on the 
formation of the possible diamine diastereomers. Reduction of 104c with NaBTL gave a 7 : 1 
mixture of tetrahydroisoquinoline diastereomers 105c and 105d, from which 105c could be 
obtained by crystallization and converted to the 1R*,1'R* diamine diastereomer 106d.# Catalytic 
hydrogénation of the deprotected dihydroisoquinoline 107 in the presence of Pd/C as catalyst 
resulted in a 1 :10 mixture of the lRM'R* (base of 106d) and 1R*,1'S* (base of 106e) diamine 
diastereomers, from which 106e could be isolated by fractional crystallization of the 
dihydrochloride salt (Scheme 21).11 
Reduction of 107 with NaBHj led to a 3 : 2 mixture of the 1R*,1'R* (106d) and 1R*,1'S* 
(106e) diamine diastereomers, while these isomers were formed in 1 : 1 ratio when 104c was 
hydrogenated under the same conditions as applied in the catalytic reduction of 107. The 
diastereomeric ratios for 105c/105d and 106d/106e were determined from the NMR spectra 
by integration of the well-separated l'-Me doublets. The relative configurations of 106d and 
106e were deduced from their ring-closed derivatives (see page 44). 
* During my PhD work, racemic compounds were prepared. Notations R* and S* refer to the relative configurations 
of the asymmetry centres. (IUPAC Rule R-7.2.2). 
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Reagents and conditions: (i): NaBH,, MeOH, 0 °C, 3 h, then r.t, 3 h, 105c : 105d = 7 : 1 , 73% 
(105c); (ii): HBr, AcOH, r.t, 30 min., 69%; (in): 1. HBr, AcOH, r.t, 30 min.; 2. NaOH, 93% 
(1+2); (iv): 1. Pd/C, H2, MeOH, r.t., 106d : 106e = 1 :10 ; 2. HC1,69 % (1+2). 
Scheme 21 
The considerable diastereoselectivity observed in the reductions of 104c and 107 can be 
rationalized by the steric effects of the methyl or Cbz groups in the dihydroisoquinolines 104c 
and 107, which are somewhat restricted conformationally by intramolecular hydrogen-bonds. 
The attack by hydride ions or hydrogen-bonds occurred from the sterically less hindered side 
of the molecule. However, the opposite diastereoselectivity observed in the reduction of 107, 
depending on the reducing agent, demands further explanation.11 
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111a 
M e O ^ ^ ^ M e 
NHCbz 
111b 
MeO' 
Reagents and conditions: (i): CICOOEt, N-Cbz-(3-alanine, EtjN, toluene, -10 °C, then reflux, 
5 min., 84%; (ii): POCI3, CHCI3, reflux, 3 h, 78%; (Hi): NaBH,, MeOH, 0 °C, 3 h, then r.t, 3 h, 
111a : 111b = 12:1,82% (111a); (iv): 1. HBr, AcOH, r.t., 30 min.; 2. NaOH, 74% (1+2). 
Scheme 22 
The 3-methyl-substituted tetrahydroisoquinoline diamine diastereomers 112 and 115 
were prepared by different synthetic pathways. (lR*,3S*)-l-(2'-Armnoethyl)-6,7~dimethoxy-3-
11 
methyl-l,2,3,4-tetrahydroisoquinoline (112) was obtained by applying a procedure analogous 
to that used for the synthesis of 106d. In the NaBbh reduction of dihydroisoquinoline 110, 
obtained in two steps from N-protected P-alanine and a-methylhomoveratrylamine (108), a 12 : 
1 mixture of tetrahydroisoquinoline isomers (1R*,3S*)-Illa and (1R*,3R*)-Illb was formed, 
from which 111a was obtained by crystallization and was converted into the pure (1R*,3S*) 
diamine diastereomer 112 by removal of the Cbz group (Scheme 22). The cis selectivity of the 
reduction can be rationalized by the steric effect of the 3-methyl group, which directs the 
hydride attack to the sterically less hindered side, resulting in 111a as the main product.72*74 The 
relative configuration (1R*,3S*) of 112 was deduced from the NOE data on H-l and H-3. 
The (1R*,3R*) diamine diastereomer 115 was prepared by LiAlTLi reduction of (1R*,3R*)-
6,7-dimethoxy-3-methyl-l,2,3,4-tetrahydroisoquinoline-l-acetamide (114), which was obtained 
in a highly diastereoselective two-step procedure7273 (monoethyl malonate addition and 
subsequent amidation) from 3-methyl-6,7-dimethoxy-3,4-dihydroisoquinoline (113) (Scheme 
23).™ 
r Y r r Y ï 
113 T 115 
114 
Reagents and conditions: ft): see ref. 73; (iiy.UAUrU, THF, reflux, 7 h, 82%. 
Scheme 23 
The starting compound for the preparation of 3-aminomethyl-l,2,3,4-tetrahydro-
isoquinoline (13) was the aminoester 116, easily available in two steps starting from DL-
phenylalanine.75 Instead of the previously reported amidation method76, the ester 116 was 
converted to the amide 117 by using methanolic NH3 solution. The carboxamide 117 was 
reduced to the corresponding tetrahydroisoquinoline diamine 13 with LiAlHi (Scheme 24).' 
0 O 
116 117 13 
Reagents and conditions: ft): NH3, MeOH, r.t, 14 d, 82%; (ii): L1AIH4, THF, reflux, 3 h, 78%. 
Scheme 10 
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3.2.2. Synthesis of tetrahydroisoquinoline hydrazino alcohols 
Regioisomeric tetrahydroisoquinoline hydrazino alcohols (14 and 124a,b) were 
synthetized from the corresponding amino alcohol derivatives (121 and 123a,b) by using the 
two-step procedure (N-nitrosation and subsequent LiAlHt reduction) usually applied for the 
preparation of N-substituted hydrazines or hydrazino alcohols from secondary amines or 
amino alcohols, respectively (Schemes 25 and 26) T^ vm 
MeO^ ... MeO. .... MeCL 
0) r Y J (a) r Y i 
y k j k f " MeO' - NH2 ~ 
COOEt COOEt 
118 119 120 
OH 
14 121 
Reagents and conditions: (i): 1. (COOEt)2, 140 °C, 6 h; 2. POCl3, PhMe, EtOH, reflux, 3.5 h, 
81%; (ii): Pt/C, H2, EtOH, r.t., 1 atm, 6 h, 82%; (ni): LiAlHt, THF, reflux, 3 h, 66%; (iv): 1. 
NaNOi AcOH, H 2 0, r.t, 8 h; 1 LiAlHt, THF, r.t., 2 h, 52%. 
Scheme 25 
With regard to its natural occurrence, a great number of procedures have been 
developed for the synthesis of the tetrahydroisoquinoline amino alcohol derivative 
calycotomine (121),78 which was obtained by LiAlhU reduction of the corresponding amino 
ester (120). Compound 120 was prepared by a three-step process starting from 
homoveratrylamine (118) (Scheme 25).79'80 
The amino alcohols 123a,b necessary for the linearly fused model compounds were 
synthetized by UAIH4 reduction of the corresponding l,2,3,4-tetrahydroisoquinoline-3-
carboxylic acids (TIC: 122a, and 6,7-diMeO-TIC: 122b) (Scheme 26) A8 7 
The long hydrolysis step of 125 towards 2-amino-3-(3,4-dimethoxyphenyl)propanoic 
acid,82 an intermediate of 122b, proved to be a tedious laboratory process on a 0.1 mol scale. 
Accordingly, an alternative procedure,83 based on a change in the sequence of the trans-
formation of the functional groups of 125, was applied for the synthesis of larger quantities of 
123b. LiAlTh reduction of 125 resulted in N-benzyl amino alcohol 126, which was converted to 
the corresponding tetrahydroisoquinoline derivative 127 by PlCTET-SPENGLER cyclization with 
formaldehyde. Removal of the benzyl group of 127 by catalytic hydrogénation in the presence 
of Pd/C led to 6,7-dimethoxy-l,2,3,4-tetrahydro-3-isoquinolinylmethanol (123b) (Scheme 26).v 
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R = H: a; R = MeO: b 
127 
Reagents and conditions: (i): LiAlHLi, THF, reflux, 8 h, 51% (123b); (ii): 1. NaN02, AcOH, H2O, 
r.t., 8 h; 2. LiAlH,, THF, r.t., 2 h, 45% (124a), 67% (124b); (in): LiAlK,, THF, reflux, 5 h, 78%; 
(iv): CH2O, HC1, H 2 0, reflux, 6 h, 92%; (v): 10% Pd/C, H^ MeOH, 30 bar, 40 °C, 30 h, 
-100%. 
Scheme 26 
3.2. Transformations of Afunctional compounds 
3.2.1. Ring-closures ivith aldehydes. Ring-chain tautomerism 
3-Aryl-substituted imidazo[5,l-a]- and -[l,5-b]isoquinolines 
Ring-chain tautomerism, the intramolecular reversible addition of a hydroxy, mercapto 
or amino group to a C=N double bond, is a characteristic phenomenon for saturated, N-
unsubstituted, five- and six-membered 1,3-X,N heterocycles (X = O, S, NR), which is often 
exploited advantageously in different areas of organic synthesis, and also in physical, 
medicinal and peptide chemistry.84'85 Substituent effects influencing the ring-chain tautomeric 
process have been thoroughly studied in recent decades. For the tautomeric equilibria of 
oxazolidines and tetrahydro-l,3-oxazines bearing a substituted phenyl group at position 2, a 
linear HAMMETT-type correlation was found between the log K (K = [ring]/ [chain]) values of 
the equilibria and the electronic character (<rf~) of the substituents X on the 2-phenyl group 
(Eq. 1), in both the liquid and the gas phase. The value of pin Eq. 1 was found to be 
characteristic of the ring system and dependent on the temperature and the nature of the 
solvent. 
log Kx - pa* + log KX-H (Eq. 1) 
Recent studies on 2-aryl-substituted imidazolidines,86'87 hexahydropyrimidines,88-90 
1,2,3,4-tetrahydroquinazolines91'92 and perhydroquinazolines93 concluded that, similarly to their 
1,3-0,N analogues, the ring-chain tautomeric equilibria of these compounds could also be 
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characterized by Eq. 1. Complex l,3-N,N-heterocyclic tautomeric mixtures containing 
regioisomeric open and/or diastereomeric cyclic forms could likewise be expressed by Eq. 1. 
For N-substituted 2-aryl-l,3-N,N heterocycles, the tautomeric process and the values of p and 
log KX=H in Eq. 1 were found to be dependent on the steric and electronic characters of the 
substituent on the nitrogen. In contrast with the 1,3-0,N analogues, the value of p proved not to 
be characteristic of the 1,3-N,N ring system.85 
As a continuation of previous studies on five- and six-membered 1,3-N,N heterocycles, 
our aim was to investigate the effects of the substituents and the position of the annelated ring 
on the ring-chain tautomeric character of some 2-aryl-substituted imidazolidine and 
pyrimidine derivatives. 
Through the condensations of diamines 11 and 13 with equivalent amounts of nine 
aromatic aldehydes, crystalline products (128a-i and 129a-i) were obtained. The 1H NMR 
spectra of 128a-i and 129a-i revealed that all of these compounds participated in three-
component ring-chain tautomeric equilibria, involving C-3 epimeric imidazoisoquinolines (B 
and C) and the corresponding SCHIFF bases (A) (Scheme 27). 
13 
128Aa-i 
128Ca-i 
129Ba-i 129Ca-i 
X = N02: a; CF3: b; Br: c; CI: d; H: e; F: f; Me: g; OMe: h; NMes i 
Reagents and conditions: (i): CHO-Cdh-X, abs. MeOH, r.t, 1 h, 68-95%. 
Scheme 27 
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After the attainment of equilibrium, the spectra of compounds 128a-i or 129a-i 
contained well-separated singlets resonating from the azomethine group at 8.31-8.46 ppm or 
8.23-8.44 ppm and the two N-CHAr-NH hydrogens in the region 4.11-4.63 or 4.22-4.92 ppm. 
The proportions Kx of the chain (A) and diastereomeric ring forms (B and C) participating in 
the tautomeric equilibria 128a-i and 129a-i were determined by integration of the well-
separated N=CHAr (chain) and N-CHAr-NH (ring) proton singlets in the !H NMR spectra 
(Table 1). The NOESY spectra revealed that the arrangements of the H-3 and the hydrogen at 
the annelation (H-an) (H-lOa for 128 and H-lOb for 129) in the major ring forms were opposite 
for the linearly and the angularly condensed imidazoisoquinolines: cis (128B) and trans (129C), 
respectively. The configuration of the azomethine double bond was found to be E. 
Table 1. Proportions (%) of tautomeric forms in tautomeric equilibria for 
compounds 128a-i and 129a-i (CDCb, 300 K) 
Compd X (f 128A 128B 128C 129A 129B 129C 
a pNOi 0.79 3.4 88.7 7.9 4.1 25.8 70.1 
b pCF3 0.612 4.8 88.2 7.0 4.7 32.0 63.3 
c pBr 0.15 7.6 86.1 6.3 14.7 28.9 56.4 
d pCl 0.114 6.9 88.0 5.1 8.1 38.1 53.8 
e H 0 9.0 86.3 4.7 12.8 28.1 59.1 
f pF -0.073 9.6 85.4 5.0 9.9 38.6 51.5 
g pMe -0.311 11.6 85.0 3.4 14.3 28.9 56.8 
h pMeO -0.778 14.3 82.5 3.2 24.3 29.5 46.2 
i pNMe2 -1.7 34.6 63.7 1.7 57.0 14.6 28.4 
When Eq. 1 was applied to the log Kx values of 128 and 129, good linear correlations 
were obtained vs the HAMMETT-BROWN parameter cf of the substituent X on the 4-phenyl 
group, for both the ds-chain and the trans-chain equilibria (Fig. 5 and Table 2). 
Table 2. Linear regression data on the equilibria of 128 and 129 
Equilibrium No. of points Slope3 (p) Intercept3 
(log Xx=H) 
Correlation 
coefficient 
128A ^ 128B 9 0.44(2) 1.02(5) 0.9821 
128A ^ 128C 9 0.65(4) 0.22(1) 0.9846 
129A ^ 129B 9 0.56(8) 0.44(7) 0.9025 
129A ^ 129C 9 0.60(6) 0.72(7) 0.9607 
Standard deviations are given in parentheses. 
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Plots of log Kx for 128B (A), 128C (•), 129B (A) and 129C (•) vs 
HAMMETT-BROWN parameter <? 
Figure 5 
Because of the inversion of the nitrogen in the tetrahydroisoquinoline-fused five-
membered saturated heterocycles, the stereostructure can be described by a conformational 
equilibrium of cis2-trans-cis2 type. In the trans structure, the B/C hetero rings are trans-
connected, with H-lOb and the N-4 lone pair trans diaxial. In the two other configurations, the 
heterorings are cis-connected, where in the cis1 conformation C-l is in the inside, while in the 
cis2 conformation C-l is in the outside position.94 
128Be 
N2 
h 
N4 
128Ce 
129Be 
b 
1 1 
Final predominant minimum energy molecular structures for 128Be, 
128Ce, 129Be and 129Ce, obtained by using ab initio HF/3-21G* calcula-
tions 
Figure 6 
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The conformational analysis of the 3-phenyl-substituted imidazo[5,l-a]- and -[1/5-hj-
isoquinolines (128e and 129e) was based on the NOESY spectra and ab initio calculations. 
Independently of the C-3 configuration, both the major and the minor isomers of the linearly-
fused imidazoisoqiiinolines (128Be and 128Ce) had a trans B/C ring connection. The 
conformation of the imidazo[5,l-a]isoquinoline was found to be dependent on the C-3 
configuration: a trans B/C ring connection was found for the minor isomer 129Be, while the 
major ring form 129Ce had a B/C ring connection of cis1 type (Fig. 6). 
The relative configuration of the cyclic tautomer exerts only a small influence on the 
values of p and the intercept (log KX=H) for the equilibria of the angularly condensed 
compounds (129), whereas considerable differences in the values of p and log KX=H were found 
for the ds-chain (128B 128A) and trans-chain (128C ^ 128A) equilibria of the linear 
imidazoisoquinolines. For the latter compounds, X-substituent-dependent hyperconjugative 
interactions were observed between the nitrogen lone pair and the C-3-attached antibonding 
orbitals. This anomeric effect is presumed to play an important role in the ring-chain 
tautomeric equilibria of conformationally inflexible 2-aryl-l,3-N,N-heterocycles.1 
4-Aryl-substituted pyrimido[6,l-fl]isoquinolines 
For the investigation of the ring-chain tautomeric character of the homologue pyrimido-
isoquinolines, diamines 106a, 106d, 106e, 112 and 115 were condensed with equivalent 
amounts of p-nitro- and p- (dime thy laminojbenzaldehyde to yield crystalline products (130-134) 
(Scheme 28). In the knowledge of the strong influence of the electronic effects of the aromatic 
substituents on the ring-chain tautomeric behaviour of 1,3-X,N heterocyclic compounds,84 85 
aromatic aldehydes were chosen according to their opposite electronic character, which favours 
the predominance of either the cyclic (in the case of p-NO2) or the open (in the case of p-NMe2) 
form. 
The proportions of the chain (A) and diastereomeric ring forms (B and C) of the 
tautomeric equlibria of 130-134 were determined, similarly as for the imidazo-isoquinolines, 
from the well-separated characteristic proton singlets in the :H NMR spectra (Table 3). The 4H 
NMR (CDCI3, 300 K) spectroscopic data on the 1-unsubstituted and 1-methyl-substituted 
model compounds (130-132) revealed that, independently of the electronic character of the 
aromatic substituents and the presence of the methyl group at position 1, their tautomeric 
equilibria were shifted totally towards the cyclic forms (B and C). 
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The NOESY spectra unequivocally showed that the major ring forms in the tautomeric 
equilibria of 130-132 contain H-4 and H-llb in the cis position (B). The proportion of the minor 
cyclic tautomer, possessing H-4 and H-llb in the trans position (C), was found to be increased 
in (lR*/llbR*)-l-methylhexahydropyrimido[6/l-fl]isoquinoline 132. 
6-Methyl substitution caused dramatic changes in the tautomeric ratios. For (6S*,llbR*)-
6-methyl-substituted hexahydropyrimido[6,l-fl]isoquinolines 133, the tautomeric equilibrium 
was found to be shifted entirely towards the open tautomer (A), even in 133a, which bears an 
electron-withdrawing p-nitro substituent on the aromatic ring. 
The tautomeric ratios determined for (6R*,llbR*)-6-methyl-substituted 4-(p-nitro-
phenyl)- (134a) and 4-[p-(dimethylamino)phenyl]hexahydropyrimido[6,l-fl]isoquinoline (134g) 
suggested that the ring-chain equilibria of these model compounds were sensitive to the 
electronic effects of the 4-aryl substituents (Table 3). Accordingly, a full set of 4-(X-phenyl)-
substituted derivatives was prepared, with substituent X exhibiting different electronic 
characters (134a-g). In consequence of the very similar NMR spectroscopic characteristics of 
134a-g, the relative configurations of the major (B) and minor (C) ring-closed tautomers were 
determined only for 134a. The proportion of the minor cyclic form (C) was found to be 
decreased to below the limit of detection in the event of strongly electron-donating 4-aryl 
substituents (p-OMe and p-NMe2). 
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Table 3. Proportions (%) of tautomeric forms (A, B and C) in tautomeric equilibria for 
compounds 130-134 (CDCb, 300 K) 
Comp. R1 R2 R3 R4 X o* A B C 
130a H H H H pNCh 0.79 0 92.6 7.4 
130b H H H H pNMez -1.7 0 100 0 
131a Me H H H pNCh 0.79 0 100 0 
131b Me H H H pNM&z -1.7 0 100 0 
132a H Me H H pNCh 0.79 0 65.4 34.6 
132b H Me H H pNMez -1.7 0 81.3 18.7 
133a H H Me H pNCh 0.79 100 0 0 
133b H H Me H pNMe2 -1.7 100 0 0 
134a H H H Me pNOz 0.79 10.7 74.7 14.6 
134b H H H Me rnBr 0.405 17.6 75.4 7.0 
134c H H H Me pBr 0.15 24.1 69.2 6.7 
134d H H H Me H 0 31.4 64.9 3.7 
134e H H H Me pMe -0.311 40.8 57.2 2.0 
134f H H H Me pOMe -0.778 54.9 45.1 0 
134g H H H Me pNMea -1.7 79.4 20.6 0 
4-Aryl substituents did not change the sequence of the chemical shifts of the 
characteristic N-CHAr-N and N=CHAr protons. The azomethine double bond configuration 
was found to be E, in accordance with the NOE interaction observed between H-2 and N=CH. 
Table 4. Linear regression data on compounds 134 
Equilibrium No. of points Slope3 (p) Intercept® 
( l o g KX=H) 
Correlation 
coefficient 
134A 134B 7 0.36(5) 0.57(6) 0.995 
134A — 134C 5 1.30(9) -0.88(6) 0.982 
Standard deviations are given in parentheses. 
When Eq. 1 was applied to the log Kx values of 134a-g, good linear correlations were 
obtained vs the HAMMETT-BROWN parameter <f of the substituent X on die 4-phenyl group for 
both the ds-chain (B-A) and the trans-chain (C-A) equilibria (Fig. 7 and Table 4). 
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Figure 7 
The data in Table 4 show that both the slope {p) and the intercept (log KX=H) of the 
regression line were strongly influenced by the relative configuration of C-4 and C-llb. The 
difference in the values of p for the ris-chain (134B=5=134A) and frans-chain (134C^134A) 
equilibria, which reflects the difference in the sensitivities of the reactions to electron supply or 
withdrawal, was found to be considerably higher (Ap = 0.94) than that observed for the ring-
chain tautomeric equilibria of the analogous 3-aryl-hexahydroimidazo[5,l-fl]isoquinolines (Ap = 
0.04).1 The different values of pfor the ds-chain (134B^=134A) and frans-chain (134C^134A) 
equilibria can probably be rationalized by the different hyperconjugative (anomeric) effects1 in 
134B and 134C, possessing different predominant B/ C ring connections. 
The substantial increase in the proportions of the open tautomers for the equilibria of 
133 and 134, as compared with the tautomeric ratios for 130-132, can be interpreted by the 
increased steric hindrance of the N-substituent caused by the 6-methyl group. Earlier data on 
the ring-chain tautomeric equilibria of l,3-N,N-heterocycles indicated that the proportion of the 
ring-closed form decreases with increasing bulkiness of the N-substituent.85 
Similarly to the tetrahydroisoquinoline-fused five-membered saturated heterocycles, 
the conformational equilibria of the tetrahydroisoquinoline-fused six-membered heterocycles 
can also be characterized as of cis^-trans-cis2 type (Figure 8). The conformational equilibria of 1-, 
2- and 4-substituted saturated l,3-oxazino[4,3-a]-,10<95 l,2,3-oxathiazino[4,3ra]-12 and 1,3,2-
oxazaphosphorino[4,3-fl]isoquinolines13'14 have been thoroughly studied, but fewer data are 
available on the analogous hexahydropyrimido[6,l-a]isoquinolines. A slight predominance of 
the conformer with trans-connected B/C rings was found for the conformational equilibrium of 
the 3-methyl-substituted parent compound in CDCI3.96 
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Figure 8 
Conformational analysis of the prepared hexahydropyrimido[6,l~fl]isoquinolines was 
performed only for the 4-(p-nitrophenyl)-substituted derivatives, which contain the cyclic 
tautomers in the highest proportions. To determine the mode of connection of the B/C rings, 
JH NMR spectroscopic methods were used, since the geometries of the B/C ring connections of 
cis1 or cis2 or trans type produce different patterns of cross-peaks derived from the 1,3-diaxial 
protons in the NOESY spectra. While the stereostructures of the major cyclic forms (B) of the 
prepared model compounds could be determined in each case (130a-132a and 134a), the 
relatively low abundance of the minor cyclic form (C) meant that its conformational analysis 
could be performed only for 132a. 
For 130aB and 131aB, the NOESY spectra showed H-llb-H-6ax, H-llb-H-4, and H-4-H-
6« NOE cross-peaks, which are typical for a B/C traws-arranged ring junction with an 
equatorial aromatic substituent. For 132aB, however, the NOESY spectrum revealed H- l -H-6ax , 
H - l l b - H - 2 a x and H-llb-H-4 NOE cross-peaks, which unequivocally proved the cis1 connection 
of the B/C rings. For 132aC, the NOESY cross-peaks for H-llb with H - 2 a X , H-6ax and the ortho 
protons of the 4-(p-nitrophenyl) substituents pointed to a trans B/C ring junction with an axial 
aromatic substituent. The NOESY cross-peaks for the (llbR*,6R*)-6-methyl-substituted C-4 
epimeric model compounds (134aB and 134aC) could be characterized by different B/C ring 
junctions: trans for 134aB (NOESY cross-peaks: H-llb-H-2ax, H-llb-H4 and H-4-Me-M, and 
equatorial and cis1 for 134aC (NOESY cross-peaks: H-llb-H-2ax and H-4-Me-6ax) with an axial 4-
(p-nitrophenyl) substituent. 
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Stereoviews of typical minimum-energy structures for 132aB and 132aC 
and for 134aB and 134aC 
Figure 9 
The structures of the C-4 epimers of 132a and 134a were confirmed by molecular 
modelling. Figure 9 depicts the typical minimum-energy molecular structures for 132aB and 
132aC and for 134aB and 134aC. The steric hindrance between H-ll and the 1-methyl group 
(for 132aB), or between the 6-methyl and 4-(p-nitrophenyl) groups (for 134aC), makes the 
predominant conformation with trans-arranged B/C rings unfavourable and shifts the 
conformational equilibrium towards the cis1 structured 
3.2.2. Tetrahydroisoquinoline diamine derivatives with multidrug resistance reversal activity 
The treatment of metastatic cancer is often unsuccessful, due to the development of 
multidrug resistance (MDR) of the tumour cells. Multidrug-resistant tumours display cross-
resistance to many classes of chemotherapeutic agents that were never part of their treatment. 
A number of studies have demonstrated that a wide range of structurally and functionally 
unrelated compounds (e.g. calcium channel blockers, calmodulin inhibitors, antimalarial agents 
and cyclosporines), are able to reverse MDR by modulation of a plasma membrane-bound 
protein (P-gp) or MDR protein (MRP1). However, since these first-generation MDR inhibitors 
are active only at high concentrations, they have proved to be of only limited relevance in 
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clinical practice. In recent years, enormous efforts have been made to find new natural or 
synthetic compounds with MDR reversal activity.97*100 
In view of the great therapeutic importance, our aim was to find new compounds with 
MDR reversal activity. In cooperation with the group of Prof, de Witte at the University of 
Leuven, ca 150 compounds prepared in recent years at the Institute of Pharmaceutical 
Chemistry were tested for MDR reversal effect. Some hits were found among 1,2-disubstituted 
tetrahydroisoquinoline derivatives containing N-thiocarbamoyl moieties, and various 
tetrahydroisoquinoline diamine derivatives were prepared to refine the structure-activity 
relationships. 
The target compounds were synthetized by using N-substitution reactions of 101, an 
intermediate of the synthesis toward tetrahydroisoquinoline diamine 11. When 101 was reacted 
with isocyanates or isothiocyanates, the corresponding urea or thiourea derivatives were 
formed in good yields (Scheme 29). 
The compounds were assayed as P-gp inhibitors in a fluorescence microtitre plate 
assay, using a standard functional assay with rhodamine 6G as a fluorescent probe on MCF-
7/Adr cells to assess MDR activity. Verapamil, a well-known MDR modulating agent, was 
used as a positive control. 
The extent of rhodamine 6G accumulation observed in the presence of the individual 
test compounds (40 pM) was expressed relative to the accumulation observed with untreated 
MCF-7/Ard cells. The accumulation factor (AF) was calculated as the mean of 3 independent 
experiments. For the compounds that displayed an AF > 3.0 (approximately the AF of 
verapamil), concentration-response curves were constructed and the ACso values (the 
concentrations of the test compounds eliciting 50% of their maximum effect on rhodamine 6G 
accumulation) were determined. Cytotoxicity was investigated on HeLa (human cervix 
carcinoma) cells, using an antiproliferative assay. Concentration-response curves were 
constructed and the IC50 values (the concentrations of the test compounds inhibiting 50% of cell 
proliferation) were determined (Table 5). Six compounds (135a-b, 135d, 135g, 135i and 135j) 
101 135a-k 
Reagents and conditions: (i): R'NCX, toluene, reflux, 1 h, 64-86%. 
Scheme 29 
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were found to have an AF > 3.0, which indicates that they are at least as effective as verapamil 
as inhibitors of P-gp. 
Table 5. Accumulation factor (AF), IC50 and EC50 values of the investigated 
tetrahydroisoquinoline derivatives and verapamil 
x ^p AC50 IC50 Ratio 
(pM) (pM) (ICso/ACso) 
135a O 8.69±0.94 7.3±0.9 14.0±3.9 1.9 
135b L II O 7.04±0.21 8.010.18 >80 >10 
"CI 
135c S 2.4910.11 
135d X ) S 3.6710.16 8.010.18 >80 >10 
135e S 2.7210.06 
.OEt 
135f S 1.7310.05 
sOEt 
135g S 3.7310.28 8.110.5 7.710.12 0.9 
135h L II S 1.5210.08 
M^e 
Me 
135i S 8.2210.52 3.910.08 7.510.48 1.9 
Me ^ ^ Me 
Et 
135j ^ O l S 5 ' 6 9 ± 0 " 5 7 3 - 8 ± 0 " 4 13.312.8 3.5 
135k ^ S 1 - 3 9 ± 0 - 0 4 
Verapamil 3.1H0.11 24.014.3 >80 >3.3 
All compoimds were found to have an AC50 significantly lower than that of verapamil. 
The respective IC50/AC50 ratios were also calculated: the larger this ratio, the less the 
compound induces a cytotoxic effect at concentrations that are effective in inhibiting P-gp, 
reversing the MDR phenotype of the treated malignant cells.'11 
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3.2.3. Phosphorus-containing 1,2,3-and 1,2,3,4-heterocycles 
Tetrahydroisoquinoline- and piperidine-fused 1,3,4,2-oxadiazaphosphinanes 
In consequence of their valuable pharmacological effects and wide-ranging possibilities 
for synthetic applications, considerable interest has been demonstrated in the 1,3,2-OrN,P-
heterocycles.v" The 1,3,2-oxazaphosphinane ring system is found in alkylating anticancer drugs 
(cyclophosphamide and ifosfamide), numerous derivatives of which have been synthetized to 
determine their structure-activity relationships.101'102 Compounds containing a 1,3,2-oxaza-
phosphinane moiety were recently reported to possess matrix metalloproteinase-
inhibitory,103'104 pesticidal105 and antimicrobial106 activities. Phosphorus-stabilized carbanions 
derived from chiral 1,3,2-oxazaphosphinane 2-oxides have been widely used in the 
diastereoselective formation of carbon-carbon bonds.107-108 
In contrast with the thoroughly investigated l,3,2-oxazaphosphinane-2-oxide 
derivatives, less attention has been paid to the synthesis and transformations of the 
corresponding l,3,4,2-oxadiazaphosphinane-2-oxides containing another nitrogen in the 
heterocyclic ring.109*113 The first representatives of this ring system were prepared with the aim 
of finding potential antitumour agents. However, despite the close structural analogy, 
cyclophosphamide-analogue l,3,4,2-oxadiazaphosphinane-2-oxides and the homologous 
l,3,4,2-oxadiazaphosphepin-2-oxides proved to exhibit very low or practically no anti-
leukaemic activity109-110 There has been only one stereochemical investigation of this ring 
system: 4-methyl-2-phenoxy-l,3,4,2-oxadiazaphosphinane-2-oxide proved to exist predomi-
nantly in the chair conformation, with the P=0 group in an axial position.111 
1,3,4,2-Oxadiazaphosphinane 2-oxides attached angularly or linearly to the tetrahydro-
isoquinoline ring were planned to be prepared in order to investigate the effects of the 
substituents and the configurations of the substituted atoms on the predominant conformations 
of the nitrogen-bridged tricyclic system. To determine the effects of the attached aromatic ring 
on the stereochemistry of the ring junction, syntheses of the parent piperidine-condensed 
derivatives were also among our aims. 
Most of the methods applied earlier for the synthesis of 1,3,4,2-oxadiazaphosphinanes 
were based on the ring-closures of the corresponding hydrazino alcohols with the appropriate 
phosphorus-containing fragments.109-111*113 This methodology was also applied for the 
preparation of our target compounds. 
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136 137 
138a,b 139a,b 
R Diastereomeric ratio (138: 
139) in the crude product 
a Ph 21:79 
b OPh 50:50 
Reagents and conditions: (i). see ref. 114.; (ii): Cl2POR, Et3N, THF, r.t., 48 h, 34-41%. 
Scheme 30 
R R1 
Diastereomeric ratio (140: 
141 or 142 :143) in the crude 
product 
140,141 a - Ph 48:52 
142,143 a H Ph 50:50 
142,143 b OMe Ph - 0 : -100 
Reagents and conditions: (i): CI2POR1, EfeN, THF, r.t, 48 h, 34-51%. 
Scheme 31 
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Hydrazinoalcohols 14, 124a,b and 137114 were cyclized with phenylphosphonic 
dichloride and phenyl dichlorophosphate at ambient temperature in THF in the presence of 
EtsN, resulting in l,6,7,8,9,9a-hexahydro-4H-pyrido[l,2-d]l,3,4,2-oxadiazaphosphinine-3-oxides 
(138 and 139), l,6,7,llb-tetrahydro-4H-l,3,4,2-oxadiazaphosphino[5,4-a]isoqirinoline-3-oxides 
(140 and 141) and 1,6,11,11 a-tetrahy dro-4H-l ,3,4,2-oxadiazaphosphino [4,5-b] isoquinoline-3-
oxides (142 and 143), which are the first representatives of these ring systems (Schemes 30 and 
31). In most cases, two P-2 epimeric diastereomers differing in the cis or trans position of the P-
substituent and H-an, were formed and were separated by column chromatography. A 
significant difference was found in the ratios of the P-2 epimers for 138a and 139a, the trans 
isomer (139a) being the main product, while in the ring-closure of 124b, the minor oxadiaza-
phosphinane diastereomer (142b) could not be detected, even in the crude product. 
Similarly to those of nitrogen-bridged saturated bi- or polycyclic heterocycles, the 
stereostructures of the 1,3,4,2-oxadiazaphosphinanes prepared (138-143) can be described by a 
conformational equilibrium of cis^trans-cis2 type.115 In the trans structure, the B/C hetero rings 
are trans-connected, with a trans-diaxial arrangement of the H-an and the nitrogen lone pair. In 
the two other configurations, the hetero rings are as-connected: for the cis1 conformation, C-l is 
in the inside, while for the cis2 conformation, C-l is in the outside position (Fig. 10). The 
phosphorus-containing 1,2,3-heterocycles are prone to participate in a conformational 
equilibrium involving chair, twisted chair and other distorted conformations.1711'14 
The stereochemistry of the model compounds was determined in two steps. First, the 
predominant conformation was assigned on the basis of the characteristic 3/ couplings and 
NOE interactions. Second, the relative configuration of the P-phenyl substituent was observed 
by using the NOEs from the P-phenyl group to the annelation protons (where applicable) 
and/or the significant differences in the chemical shifts for certain indicator nuclei. 
H 
trans cis2 
Possible ring connections of 1,6,7,8,9,9a-hexahydro-4H-pyrido[l,2-d]-
[l,3,4,2]oxadiazaphosphinines 
Figure 10 
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NOE 
NOE H 
H 7 
3p^Ph 
141a 
H H Ph 
NOE H 1 
138a, b; 139a, b 143a,b 
Detected NOEs 
Figure 11 
The orientation of H-an (i.e. H-llb for 140a and 141a; H-lla for 142 and 143; and H-9a 
for 138 and 139) and the protons connected to the carbons adjacent to the annelation (H-l and 
H-X; H-X: H-l l for 142 and 143, and H-9 for 138 and 139) or the protons connected to the 
carbons adjacent to the nitrogen-bridge (H-6) were assigned by using the vicinal coupling 
constants (Table 6) and the detected NOESY cross-peaks (Fig. 11). 
The data in Table 6 show that H-an for 143a,b, 138a,b and 139a has two high vicinal 
couplings to the axial protons connected to the carbons adjacent to the annelation (H-X, i.e. H-
11 for 142a,b and 143a,b; and H-9 for 138a,b and 139a,b), indicating that H-an is in the axial 
position and the hetero rings are trans-connected. The vicinal couplings of H-l lb for 140a and 
141a correspond to a trans diaxial position for H-l lb and H - l a x , which excludes the hetero ring 
connection of cis2 type. The NOESY cross-peaks detected for H-l lb and H-6ax indicate the trans 
connection of the hetero rings for both compounds. 
Table 6. Characteristic vicinal coupling constants (in Hz)* 
Compd. H - l a x - H - a n H- leq-H-an H-Xax-H-an H-Xeq-H-an H - l a x - P H - l e q - P 
138a 9.8 3.3 10.1 2.8 3.5 18.9 
139a 10.3 3.0 10.0 3.1 2.0 20.4 
138b 10.6 3.5 10.1 3.0 1.6 19.9 
139b 9.0 3.5 overlap overlap 2.3 26.4 
140a 9.3 4.3 - - 5.3 17.1 
141a 10.6 2.8 - - 1.3 18.6 
142a 4.0 2.5 11.8 5.5 3.8 20.0 
143a 9.8 4.0 10.6 4.8 7.3 18.4 
143b 8.2 3.8 10.3 4.8 8.1 18.1 
*For the meanings of H-an and H-X, see the text. 
For 142a, the 3/(H-lax-H-lla) and 3/(H-leq-H-lla) values were 4.0 and 2.5 Hz, 
respectively, which suggest that H-an is equatorial to the oxadiazaphosphinane ring. This is 
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supported by the equally strong NOE from H-lla to both H-l protons. The vicinal couplings 
between H-lla and protons H-ll show an axial orientation of H-lla with respect to the 
isoquinoline ring. These findings are in accord with two possible conformations: a cis2-
connected chair-chair and a frans-connected chair-boat. In order to decide between these, ab 
initio molecular modelling was performed at the HF/6-31* level. The calculations revealed that 
conformation cis2 is 5.3 kcal/mol more stable, and we therefore believe that the hetero rings are 
predominantly cis-connected (cis2 conformation; Fig. 12). 
Ab initio geometry obtained for 142a 
Figure 12 
As concerns the orientation of the P-substituent, P-Ph-H-lax NOE interactions could 
readily be detected in 141a and 143a,b (Fig. 11), which indicates the axial arrangement of the P-
phenyl group and its position trans to H-an (H-llb or H-lla, respectively). 
P-Ph-H-lax or P -OPh-H- lax NOE interactions could not be determined unambiguously 
for compounds 138a and 139a, and the P-configuration was therefore deduced from the 
chemical shifts calculated by using the GIAO method at the HF/6-31G* level and the 
geometrical constraints obtained by means of NMR. It is a trend that H - l a x exhibits an upfield 
shift in compounds containing an axial P-phenyl group (i.e. trans to H-an), due to the ring 
current shielding. 
The comparison of the experimental and theoretical chemical shifts (Table 7) 
unambiguously corroborated the assignment. Unfortunately, the phenoxy derivatives (138b 
and 139b) did not allow utilization of the shielding effect because of the flexible aromatic 
substituent; the stereochemical assignment is therefore based purely on the X-ray data. 
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Table 7. Experimental and calculated characteristic 
chemical shifts (in ppm) (¿tms = 0, «foq = 0) 
H-lax H-l 
Compd. 
Exp. Calcd. Exp. Calcd. 
138a 4.42 3.97 4.13 3.45 
139a 3.78 3.02 4.16 3.39 
138b 4.23 3.69 4.17 3.18 
139b 4.26 3.73 4.31 3.50 
140a 4.72 4.09 4.58 3.91 
141a 4.05 3.29 4.72 3.87 
142a 4.44 3.27 4.32 3.48 
143a 3.99 3.04 4.51 3.53 
143b 3.97 3.01 4.46 3.49 
The steric assignment of the P-2 epimers of 138 and 139, based on the results of NMR 
experiments and theoretical calculations, was in accordance with the X-ray crystal structures of 
139a and 139b (Fig. 13) Y 
The stereochemical assignments for 138-143 are presented in Table 8. 
Table 8. Stereochemical assignments for 138-143 
Compd. 
Steric position of H-an 
and the P-substituent 
Stereochemistry of the 
junction of the hetero 
rings 
Oxadiazaphosphinane 
ring conformation 
138a cis trans chair 
139a trans trans chair 
138b cis trans chair 
139b trans trans chair 
140a cis trans chair 
141a trans trans chair 
142a cis cis chair 
143a trans trans chair 
143b trans trans chair 
The chair conformation found for 1,3,4,2-diazaphosphinanes angularly fused to 
tetrahydroisoquinoline (140a, 141a) is substantially different from the steric structures of the 
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analogous l,3,2-oxazaphosphino[4,3-«]isoquinolines, which could be characterized by distorted 
conformations of the 1,3,2-oxazaphosphinane ring.14 
l,3,2-Diazaphosphino[6,l-a]isoquinolines 
In contrast with the l,3,2-oxazaphosphinane-2-oxides, which have been thoroughly 
investigated from both pharmacological and stereochemical points of view,14-102 less attention 
has been paid to the synthesis and stereochemistry of the aza-analogue 1,3,2-
diazaphosphinane-2-oxides. The first publications on the conformations of saturated 1,3,2-
diazaphosphinane 2-oxides contained much uncertainty concerning the axial/equatorial 
orientation of the P-substituents.116-119 The stereochemical investigations of this type of 
heterocyclic compounds became of considerable interest when chiral phosphoramides proved 
to be effective auxiliaries with which to induce stereoselective carbon-carbon or carbon-
hydrogen bond-forming reactions, e.g. asymmetric aldol reactions,120-122 allylations of 
aldehydes,123 a-alkylations of P-alkyl derivatives124 and reductions of ketones.125 Stereochemical 
studies on some l,3,2-diazaphosphinane-2-oxide model compounds led to the conclusion that, 
in contrast with the conformationally diverse 1,3,2-oxazaphosphinane analogues, these 
compounds could be characterized by chair or flattened chair conformations.126'127 
The ring-closure reactions of diamines 106a-e with phenylphosphonyc dichloride were 
accomplished by the usual literature methods,128 to yield l,3,2-diazaphosphino[6,l-«]iso-
quinolines (144 and 145), which are the first representatives of this ring system (Scheme 32). 
The N-substituents proved to have significant effects on the ratios of the diastereomers formed: 
in the case of the N-unsubstituted diamines (106a,d,e) the diastereomers of type 144, containing 
a 4-phenyl group and H-llb in the eis position, were the major isomers, while the N-phenyl-
X-ray crystal structures of 139a and 139b. The thermal displacement 
ellipsoids are drawn at a probability level of 30% 
Figure 13 
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and N-methyl-substituted diamines (106b,c) gave isomers of type 145 as the main products. In 
the ring-closure of the 1R*,1'R* l'-methyl-substituted diamine diastereomer (106d), the minor 
diazaphosphinane isomer of type 145 could not be detected, even in the crude product. 
Me(X 
MeO (9 
Ri R2 R3 Diastereomeric ratio (144 :145) 
in the crude product 
a H H H 56:44 
b Ph H H 29:71 
c Me H H 27:73 
d H Me H -100 : - 0 
e H H Me 57:43 
Reagents and conditions: (i): PhPOCl2/ Et3N, CH2CI2,6-10 °C, 24 h, 25-49%. 
Scheme 32 
For compound 145, a systematic increase in the chemical shifts of H-2ax is detected as 
compared with compounds 144 (Table 9), which is due to the shielding effect of the oxygen in 
the 1,3-diaxial position relative to H-2a* (H-2ax is assigned because of the NOE interaction with 
H-llb.) The NOE interactions between the ortho-hydrogens of the phenyl group on the 
phosphorus and H-llb can be detected in each case in the series 144. These findings 
unequivocally show that H-llb and the phenyl substituent on the phosphorus are located on 
the same side of the best plane of the diazaphosphinane ring in 144. The assignment of the 
relative configuration is supported by the 31P chemical shifts; an upfield shift is measured for 
the 31P chemical shifts on going from 144 to 145, with the exception of the diastereomeric pair 
144a and 145a (Table 9). As a consequence of the diastereomeric counterpart not being 
available, the spatiality of 144d was assigned purely on the basis of the observed NOE 
interactions. 
As regards the relative configurations 144d, 144e and 145e, the 3/(H-l,H-llb) couplings 
are informative. For 144d, the coupling constant of 9.2 Hz between H-l and H-llb proves their 
frans-diaxial arrangement. The low 3/(H-l,H-llb) values of 2.8 and 2.9 Hz observed in 144e and 
145e, respectively, indicate almost orthogonal geometry for the vicinal protons in question, 
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proving their as-axial-equatorial relative configuration. In consequence of the synthetic 
pathway, these are also the relative configurations of the starting diamines 106d and 106e. 
Table 9. Selected chemical shifts and vicinal coupling constants 
¿ 3 1 P S H2ax S H2eq 3/(H-llb,P) 3/(H-2ax,P) 3/(H-2eq,P) 37(H-llb,H-leq) 3/(H-llb,H-l«) 
144a 26.0 3.35 3.44 2.8 5.0 22.1 6.8 9.0 
145a 24.9 3.54 3.33 2.9 6.0 21.8 3.3 11.9 
144b 22.5 3.89 3.73 3.3 11.3 16.6 5.5 8.8 
145b 23.1 4.00 3.63 4.4 6.6 16.2 4.2 10.8 
144c 25.2 3.46 3.25 2.6 4.0 17.0 4.4 9.9 
145c 29.1 3.54 3.08 2.2 4.7 20.9 2.0 11.6 
144d 28.6 2.91 3.47 4.8 10.8 18.6 - 9.2 
144e 24.7 3.56 3.23 1.8 3.5 24.3 2.8 -
145e 29.4 3.87 3.11 3.5 5.6 23.5 2.9 -
The chemical shifts (6) are given in ppm, and the coupling constants (3J) are given in Hz. 
The phosphorus-containing heterocycles are prone to participate in a conformational 
equilibrium involving chair, twisted chair and other distorted conformations (A-E)14 (Figure 
14). This conformational flexibility stems from the greater bond lengths associated with the 
phosphorus. The straightforward way to obtain information on the conformational equilibria of 
the model compounds is analysis of the 3J(P,H) coupling constants, which allows estimation of 
the dihedral angle distribution by using the following formula: 
PB = (3/obs -3/A)/(3JB - 3JA), PA = 1-PB (Eq. 2) 
where PA and PB are the populations, 3/OBS is the experimentally observed coupling constant, 
and 3/A and 3JB are the reference coupling constants in states A and B, respectively. On the basis 
of the literature data,13'14129130 estimated reference values of 25 and 3 Hz are chosen for 3/(P,Heq) 
and 3/(P,Hax), respectively. The low values observed for 3/(P,H-llb) clearly show its 
predominantly axial orientation in the diazaphosphinane ring (Table 9), which rules out 
conformers B and D containing an equatorial H-llb, and points to conformers A and C. For 
144d and 145b, a slightly increased 3/(P,H-llb) value is observed, suggesting that the 
conformation reflects a degree of similarity to the flattened ring geometry of E and F;14 
however, we describe the present diazaphosphinane ring conformations as involving an 
equilibrium between the idealized conformers A and C. The estimated ratios are given in Table 
10. 
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Possible conformations of 1,3,2-diazaphosphinanes (X = NR') and the 
related 1,3,2-oxazaphosphinanes14 (X = O) 
Figure 14 
The sum of the conformer populations calculated independently from 3/(P,H-2eq) and 
3/(P,H-2ax) significantly exceeds 100% for 145b and 144c, where N-3 possesses Me or Fh 
substituents. Such anomalous behaviour of the coupling constants can be explained by the 
assumption of distorted conformational states differing from A and C, which might be caused 
by unfavourable 1,2 interactions between the substituents on N-3 and P.11 
Table 10. Conformer populations (%) 
[A] [C] [A] +[C] 
144a 91 13 104 
145a 87 15 101 
144b 62 38 100 
145b 84 40 124 
144c 95 36 132 
145c 92 19 111 
144d 65 29 94 
144e 98 3 101 
145e 88 7 95 
As concerns the conformation of the annelated isoquinoline moiety, the vicinal coupling 
constants between H-6ax and H-7ax lie in the interval 7.9-11.8 Hz, indicating their diaxial 
orientation. A NOESY cross-peak between H-llb and H-6ax can be observed for each 
compound. These spectral parameters render the twist conformation likely for the 
tetrahydroisoquinoline moiety, which is a general feature of tetrahydroisoquinoline derivatives 
condensed angularly to a saturated 1,3- or 1,2,3-heterocycle.12*15 
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4. SUMMARY 
During my PhD studies, tetrahydroisoquinoline difunctional compounds, diamines and 
hydrazino alcohols, were prepared and their transformations towards isoquinoline-condensed, 
saturated 1,2-, 1,2,3- and 1,2,3,4-heterocycles were investigated. Both the ring-chain tautomeric 
and conformational equilibria of the prepared tricycles were sensitive to the steric and/or 
electronic effects of the substituents and the relative configurations of the substituted atoms. 
The main findings are as follows: 
1. Starting from homoveratrylamine and N-Cbz-protected glycine or P-alanine, 1-
aminomethyl- (11) and l-(2'-aminoethyl)-6,7-dimethoxy-l,2,3,4-tetrahydroisoquinoline 
(106a) were prepared by a convenient four-step process (acylatian, BlSCHLER-NAPIERALSKI 
ring-closure, reduction and deprotection). This synthetic method was successfully 
extended to substituted p-alanine (N-phenyl or a-methyl) and homoveratrylamine (a-
methyl) derivatives. 
NaBHt reductions of 1'- or 3-methyl-substituted l-[2'-(Cbz-amino)ethyl]-6,7-dimethoxy-
3,4-dihydroisoquinoline (104c and 110) proved to be highly stereoselective processes 
yielding 7 : 1 (105c : 105d) or 12 : 1 (111a : 111b) mixtures of the corresponding 
diastereomers, from which die main products could easily be isolated and converted to 
the diamines (1R*,1'R*)-I06d and (1R*,3S*)-112. 
In the case of the l'-methyl-substituted 104c, the reducing agent applied and the sequence 
of the reduction and deprotection steps proved to have marked effects on the formation 
of the possible diamine diastereomers. Catalytic hydrogenation of the deprotected 
dihydroisoquinoline 107 in the presence of a Pd/C catalyst resulted in the diamine 
(1R*,TS*)-I06e with a high diastereomeric excess. 
The (lR*3R*)-3-methyl-substituted diamine diastereomer 115 and 3-aminomethyl-l,2,3,4-
tetrahydroisoquinoline (13) were prepared by LiAlHi reduction of the corresponding 
known carboxamides (114 and 117). 
2. By using the two-step procedure (N-nitrosation and a subsequent LiAfflU reduction) 
usually applied for the synthesis of hydrazine derivatives, l-hydroxymethyl-6,7-
dimethoxy-l,2,3,4-tetrahydroisoqiiinoline (calycotomine: 121) and the regioisomeric 3-
hydroxymethyl analogues (123a,b) were converted to the corresponding tetrahydro-
isoquinoline hydrazino alcohols (14 and 124a,b). 
3. Condensation of the prepared tetrahydroisoquinoline 1,2- and 1,3-diamines containing a 
primary amino group (11,13,106a, 106d, 106e, 112 and 115), with aromatic aldehydes 
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resulted in 3-aryl-substituted hexahydroimidazo[5,l-a]- (129) and [l,5-&]isoquinolines 
(128) and 4-aryl-substituted hexahydropyrimido[6,l-a]isoquinolines (130-134). The ling-
chain tautomeric character of the prepared imidazo- and pyrimido-isoquinolines was 
studied by means of 1H NMR spectroscopy in CDCI3 at 300 K. The ratios of the tautomeric 
forms were determined by integration of their characteristic protons. 
4. Both linear and angular imidazo-isoquinoline derivatives (128 and 129) proved to 
participate in three-component ring-chain tautomeric equilibria, which could be 
characterized by HAMMETT-type correlations. The relative configuration of the cyclic 
tautomer was found to exert only a small influence on the values of p and the intercept 
(log KX=H) for the equilibria of the angular compounds (129), whereas considerable 
differences in the values of p and log KX-H were found for the czs-chain (128B-128A) and 
trans-chain (128C-128A) equilibria of the linear analogues, which could be explained by 
the different hyperconjugative (anomeric) effects observed between the nitrogen lone pair 
and the C-3-attached antibonding orbitals in the C-3 epimeric ring forms. 
5. The ring-chain tautomeric equilibria of the 1-unsubstituted and 1-methyl-substituted 4-
aryl-9,10-dimethoxy-13,4,6,7,llb-hexahydrcK2H-pyrimido[6,l-a]isoquinolines (130-132) 
were shifted quantitatively towards the cyclic forms, while for the (6S*,llbR*)-6-methyl-
substituted derivative 133, the tautomeric equilibrium was shifted quantitatively towards 
the open tautomer. The ring-chain tautomeric equilibrium of the (6R*,llbR*) 6-methyl-
substituted derivatives was sensitive to the electronic effects of the 4-aryl substituents and 
could be characterized by HAMMETT-type equations. The different values of p for the ris-
chain (134B-134A) and trans-chain (134C-134A) equilibria could be rationalized by the 
different hyperconjugative (anomeric) effects in 134B and 134C. 
6. The conformational equilibria of cis^-trans-cis2 type of die prepared imidazo- and 
pyrimidoisoquinolines were investigated by NMR and computational methods. For 
linearly-fused imidazo[l,5-b]isoquinolines, trans-connected B/C rings were found for 
both the major and the minor cyclic forms. The preferred conformations of the angular 
imidazo[5,l-a]isoquinoline proved to be dependent on the C-3 configuration: trans B/C 
rings for the minor (129Be) and ris1 B/C rings for the major cyclic form 129Ce. 
For 4-(p-nitrophenyl)hexahydropyrimido[6,l-a]isoquinolines, methyl substituents at 
positions 1 and 6 and the relative configurations of C-l, C-4 and C-llb exerted strong 
effects on the conformation. The steric hindrance between H-ll and the 1-methyl group 
or between the 6-methyl and 4-(p-nitrophenyl) groups makes the predominant 
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conformation with trans-arranged B/C rings unfavourable and shifts the conformational 
equilibrium towards the cis1 structure. 
7. By N-substitution reactions of l-(Cbz-aminomethyl)-6/7-dimethoxy-l/2/3,4-tetrahydroiso-
quinoline (101) with isocyanates or isothiocyanates, the corresponding urea or thiourea 
derivatives were obtained, which were assayed as P-gp inhibitors to determine their 
MDR reversal activity. Six of the tested compounds were at least as inhibitory as 
verapamil, a well-known MDR-modulating agent, against P-gp. 
8. The hydrazino alcohols 14, 124a,b and 137 were cyclized with phenylphosphonic 
dichloride and phenyl dichlorophosphate, resulting in saturated pyrido[l,2-d]l,3,4,2-
oxadiazaphosphinine-3-oxides (138 and 139), l,3,4,2-oxadiazaphosphino[5,4-a]isoquino-
line-3-oxides (140 and 141) and l,3,4,2-oxadiazaphosphino[4,5-fr]isoquinoline-3-oxides 
(142 and 143) as the first representatives of these ring systems. 
By similar ring-closures of diamines 106a-e with phenylphosphonyc dichloride, 1,3,2-di-
azaphosphino[6,l-fl]isoquinolines (144 and 145) were prepared. The N-substituents 
proved to have significant effects on the ratios of the diastereomers formed: in the case of 
the N-unsubstituted diamines (106a, d,e), the diastereomers containing a 4-phenyl group 
and H-llb in the cis position, were the major isomers, while the N-phenyl- and N-methyl-
substituted diamines (106b,c) gave the isomers with the opposite geometry as the main 
products. 
9. The NMR and X-ray conformation analysis on 138-143 revealed that, independently of the 
P-substituent and the relative configuration of the phosphorus atom, 138-141 could be 
characterized by frans-connected hetero rings and the chair conformation of the 1,3,4,2-
oxadiazaphosphinane moiety, while the stereochemistry of the connection of the hetero 
rings (trans or cis2) was found to be dependent on the P-configuration relative to that of 
the carbon at the annelation in the case of 1,3,4,2-oxadiazaphosphinanes linearly fused to 
tetrahydroisoquinoline (142 and 143). 
Conformational analysis of 144 and 145 led to the conclusion that H-an (H-llb) takes up 
an axial position (relative to the 1,3,2-diazaphosphinane ring) in each case and the 
conformational behaviour of these compounds can be characterized by the equilibria of 
conformers having a chair and a twisted chair 1,3,2-diazaphosphinane ring. The 
conformer populations were also influenced by the substituents at positions 1 and 3, and 
by the relative configurations of C-llb and C-l or P-4. 
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